1 / 3
We are the pioneer in the development of global oligonucleotide drugs, committed to the development of RNA interference (RNAi) technology and industrialization of oligonucleotide drugs. We have established oligonucleotide therapeutic platform that vertically integrates the complete set of technologies to support the full life cycle of oligonucleotide therapeutics from early R&D to commercialization. We have built a globally integrated oligonucleotide drug development capability and have established a robust siRNA drug pipeline through independent innovation, covering cardiovascular, metabolic, renal， liver and other diseases, especially in the field of chronic disease treatment.
We are committed to the iterative innovation of oligonucleotide chemical modification and drug delivery technologies, also possess special competitive advantages in multi-target drug design and other technologies. Among them, our liver-targeted delivery platform RiboGalSTARTM, has been validated in clinical trials of multiple product pipelines. RiboOncoSTAR™ is the world's leading tumor-targeting technology platform that supports the development of a variety of potential first-in-class oncology therapies, and the RiboPepSTAR™ technology platform has demonstrated significant efficacy in renal and central nervous system delivery over existing therapies in a number of disease models with favorable safety profile.
We have rich pipelines. We are at the forefront of oligonucleotide drug innovation focused on development of innovative drugs for cardiovascular, metabolic, renal and liver diseases, as well as other therapeutic areas. We currently have six in-house discovered siRNA drugs in clinical trials, and four of them entered phase Ⅱ. In addition, we have over twenty preclinical pipelines that continue to advance.
RBD4059
Thromboembolism
RBD5044
Hyperlipidemia
RBD7022
Hyperlipidemia
RBD1016
HBV
RBD7007
Renal Diseases
RBD2080
Renal Diseases
